Depression | Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Depression research study
What is the primary objective of this study?
The Purpose of this study is to predict antidepressant response in advance using pharmacogenomics and peripheral biological markers in depressed patients.
Who is eligible to participate?
Inclusion Criteria: 1. 25 < age <85 2. major depressed patients satisfied with the diagnosis criteria depression of DSM-IV 3. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians Exclusion Criteria: 1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks 2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Antidepressant Drug Adverse Reaction
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:SSRI treated groupAntidepressant administration of SSRI class for 6 weeks under therapeutic dose
Drug:non-SSRI treated groupAntidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
SSRI treated groupSSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
non-SSRI treated groupnon-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
Start Date: April 2006
Completed Date: March 2018
Primary Outcome: all pharmacogenetic and biological marker variables cause drug response
Secondary Outcome: all clinical cause drug response
Study sponsors, principal investigator, and references
Principal Investigator: Doh Kwan Kim, M.D.,Ph.D.
Lead Sponsor: Samsung Medical Center